Traction
Momentum across capital, clinic and channel.
Backed by leading Nordic investors and progressing toward integrated distribution through the imaging platforms clinicians already use — with an interdisciplinary team, strong IP and a maturing clinical evidence base.
IP
Strong patent applications filed
Market
Collaboration with leading distributors and hospitals
TRL
5
Research
Several high-impact publications
Team
Interdisciplinary expert founders
Investments
€700k+
Roadmap
2020–2023
Research
Strong research funding attracted
2023
Foundation
Key entrepreneurs in incubator programs
2024
Soft funding
Strong grant attraction
2025
Pre-seed round
€50k — LiU Invest
2026
Seed round
€650k — Almi Invest, East Sweden Capital et al.
2027
Pre-Series A
Clinical studies & MDR 2A path
2028
Clinical launch
CorASCT · MDR 2A clearance
2029
Scaling
NAM expansion · FDA clearance
Cap table
Our investors.
An oversubscribed SEK 7M seed round closed in 2026, led by Almi Invest and East Sweden Capital — with continued backing from LiU Invest and a group of experienced private investors.
Lead investors
- Almi Invest
- East Sweden Capital
Follow-on
- LiU Invest
New investors — seed round 2026
- Cygne Invest
- Henrik Lewander Invest and Management
- HMBV
- MThor Holding
Non-dilutive support
- Vinnova
- LEAD incubator
Market
A €4.5B opportunity hiding in plain sight.
CorASCT addresses converging clinical workflows across ablation therapy, stroke care and anticoagulation decisions — defining a meaningful addressable market for an integrated, CT-native solution.
Ablation priority
€1.0B
Stroke care
€1.5B
NOAC decision
€2.0B
TAM
€0.0B
Total addressable
SAM
€0.0B
Serviceable
SOM
€0M
5-year obtainable
Cordicity
More than improved imaging.
Talk to the team building the next quantitative marker in stroke care — whether you are a clinician, a partner, an investor or a future colleague.